7-Amino-3-[(Z)-2-(4-Methylthiazole-5-Yl)Ethenyl]-3-Cephem-4-Carboxylic Acid

Product Name 7-Amino-3-[(Z)-2-(4-Methylthiazole-5-Yl)Ethenyl]-3-Cephem-4-Carboxylic Acid
Alias Cefixime
Einecs 672-587-8
Mininmum Order 1mg
Factory Site West Ujimqin Banner, Xilingol League, Inner Mongolia, China
Price Inquiry sales9@bouling-chem.com
Manufacturer Bouling Chemical Co., Limited
CONTACT NOW

In terms of specification, 7-Amino-3-[(Z)-2-(4-Methylthiazole-5-Yl)Ethenyl]-3-Cephem-4-Carboxylic Acid is supplied with purity (HPLC) and Z-isomer content, making it suitable for the synthesis of Cefditoren Pivoxil.

Specifications

HS Code	704441
Chemical Formula	C13H14N4O3S2
Molar Mass	354.41 g/mol
Appearance	Typically a solid
Solubility In Water	Low solubility
Solubility In Organic Solvents	Soluble in some polar organic solvents
Melting Point	Specific value would require experimental determination
Pka	Multiple pKa values due to acidic groups
Stability	Can be sensitive to light, heat, and moisture
Functional Groups	Amino, carboxylic acid, thiazole, ethenyl, cephem ring

As an accredited 7-Amino-3-[(Z)-2-(4-Methylthiazole-5-Yl)Ethenyl]-3-Cephem-4-Carboxylic Acid factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

Packing & Storage

Packing	Packaging: Bottle containing 100g of 7 - Amino - 3 - [(Z) - 2 - (4 - Methylthiazole - 5 - Yl)Ethenyl] - 3 - Cephem - 4 - Carboxylic Acid.
Shipping	Ship 7 - Amino - 3 - [(Z)-2-(4 - Methylthiazole - 5 - Yl)Ethenyl]-3 - Cephem - 4 - Carboxylic Acid in well - sealed, corrosion - resistant containers. Ensure compliance with chemical shipping regulations for safe transportation.
Storage	Store "7 - Amino - 3 - [(Z)-2-(4 - Methylthiazole - 5 - Yl)Ethenyl]-3 - Cephem - 4 - Carboxylic Acid" in a cool, dry place. Keep it away from direct sunlight and heat sources to prevent degradation. Store in a tightly - sealed container to avoid moisture absorption and contact with air, which could potentially react with the chemical and reduce its stability.

Application of 7-Amino-3-[(Z)-2-(4-Methylthiazole-5-Yl)Ethenyl]-3-Cephem-4-Carboxylic Acid

Adoption of cephem nuclei with a 3-vinylthiazole substituent in industrial antibiotic manufacture is dictated by the intersection of β-lactam ring stability during downstream conjugation and the steric demands of acylation at the C-7 amine. For 7-Amino-3-[(Z)-2-(4-methylthiazole-5-yl)ethenyl]-3-cephem-4-carboxylic acid, the (Z)-geometry of the ethenyl linker and the electron density distribution within the thiazole ring establish two non-negotiable processing boundaries: a thermal degradation onset at 138 °C (DSC, 10 K/min under nitrogen, onset extrapolated per ASTM E537-20), and molecular crosslinking in the presence of triethylamine above 25 °C due to Michael-type addition across the vinyl moiety. These constraints propagate into every downstream unit operation, from acylation solvent selection to spray-dried powder isolation.

Granulation Anomalies in Cefdinir Monohydrate Crystallization

The synthesis of cefdinir, specifically the monohydrate stable Form I, initiates with the acylation of the C-7 amine using (Z)-2-(2-aminothiazol-4-yl)-2-trityloxyiminoacetyl chloride hydrochloride in a dichloromethane/water biphasic system maintained at −12 °C ± 2 °C. This is not a generic N-acylation; the trityloximino group introduces steric hindrance that suppresses the competing Δ² to Δ³ isomerization, a side reaction that produces 1.2–1.8 area% of an impurity with a relative retention time of 1.34 against the cefdinir peak (HPLC, C18, 254 nm). A molar excess of 1.05:1 (activated acid:cepheme starting material) is employed; exceeding 1.12:1 generates a di-acylated byproduct at a rate of 0.13 mol%/h during the hold step, accumulating in the organic phase. Post-acylation, the protected intermediate undergoes solvolysis with aqueous formic acid (content of 98%) to remove both the trityl and p-methoxybenzyl ester protecting groups. The free carboxylate is extracted into an aqueous phase adjusted to pH 2.5–2.8 with dilute HCl. Crystallization is seeded with ASTM E11 sieved (75 µm mesh) Form I crystals and the precipitation is driven by pH adjustment to the isoelectric point (3.9–4.1) using aqueous sodium bicarbonate under a controlled linear ramp of 0.15 pH units/h. Deviation from this ramp rate, particularly exceeding 0.25 pH units/h, results in oiling-out and formation of the metastable polymorph Form II, which exhibits a powder x-ray diffraction peak at 2θ = 14.7° and a water content by Karl Fischer of < 1.5%. Compliance with ICH Q6A is demonstrated via specific optical rotation [α]^D²⁰ = +58° to +66° (c = 1, 0.05M phosphate buffer, pH 7.0) and total aerobic microbial count per USP <61>. The terminal pharmaceutical form is a 300 mg capsule containing cefdinir monohydrate blended with carboxymethylcellulose calcium, magnesium stearate, and polyoxyl 40 stearate, targeting a dissolution profile of not less than 85% (Q) in 30 minutes per USP <711> Apparatus II at 50 rpm in 0.1N HCl.A critical processing bottleneck manifests downstream in the powder handling line: cefdinir monohydrate exhibits a median particle size (D50) shift from 18 µm to 63 µm during pneumatically conveyed transfer over a distance exceeding 12 m in a dilute-phase vacuum system operating at −0.6 bar. This agglomeration is not triboelectric charging but a liquid-bridge mechanism driven by partial dehydration at the crystallite surface. The root cause is a localized temperature spike to 47 °C in the rotary valve pockets, triggering release of lattice water that condenses on cooler surfaces. Mitigation employs a nitrogen-purged rotary valve with a tip speed limited to 0.8 m/s and a jacketed conveying line held at a constant ± 1.2 °C of the crystallization mother liquor temperature.

What Governs C-3 Vinyl Orientation During Diastereomeric Salt Resolution of Cefixime Trihydrate?

Production of cefixime trihydrate via the reactive-form of the cephem leverages the natural (Z)-configuration of the ethenylthiazole to anchor a chiral resolution step absent in synthetic routes requiring post hoc isomerization to the (E)-form. The C-7 amine is coupled with a pre-assembled side chain, (Z)-2-(2-aminothiazol-4-yl)-2-[(carboxymethoxy)imino]acetic acid, using an active ester method. The activated ester, typically a 2-mercaptobenzothiazole (MBT) derivative, is added in a single charge (1.3 molar equivalents) to a dimethylacetamide (DMAc) suspension of the cephem and triethylamine (1.5 eq) at −15 °C. Process analytical technology (PAT) monitoring via ReactIR tracks the disappearance of the anhydride carbonyl stretch at 1825 cm⁻¹ with a reaction endpoint accepted when the signal intensity falls below a threshold of 0.003 AU. Ester hydrolysis of the p-methoxybenzyl ester protecting group employs titanium tetrachloride (3.2 eq) in anhydrous dichloromethane with anisole (5 eq) as a cation scavenger. The hydrolysis vessel is inerted with argon, and the TiCl₄ is added via a PTFE-lined dosing line at a rate maintaining internal temperature below −10 °C due to an adiabatic temperature rise of 185 kJ/mol exotherm. Following acidic aqueous quench at 4 °C, the cefixime free acid is extracted into ethyl acetate, dried over molecular sieves (3A), and crystallized as the dihydrate sodium salt. The final trihydrate is isolated by dissolving the sodium salt in water, clarifying through a 0.2 µm polyethersulfone membrane, and precipitating by dropwise acidification to pH 3.2. The suspension is stirred under a controlled cooling protocol from 25 °C to 2 °C over 8 hours (ramp: 2.8 °C/h) to promote trihydrate lattice incorporation without capturing the tetrahydrate phase, which is thermodynamically preferred at activity of water (a_w) > 0.95. Residual solvents are verified against USP <467> Class 2 limits, specifically ensuring DMAc content is not more than 1090 ppm. The termination of the particle engineering sequence produces a granulated final dosage form: a 400 mg dispersible tablet comprising cefixime trihydrate (447.63 mg) with crospovidone (24 mg), microcrystalline cellulose, and colloidal silicon dioxide, requiring a friability of less than 1.0% per USP <1216>.

Processing Parameter	Cefdinir Monohydrate (Form I)	Cefixime Trihydrate	Analytical Method/Standard
Acylation Activator/Method	Acid Chloride, Schotten-Baumann	MBT Active Ester in DMAc	In-process HPLC at 254 nm
C-7 Acylation Temperature Window	−14 °C to −10 °C	−18 °C to −12 °C	Calibrated Pt100 probe, ± 0.3 °C
Protecting Group Removal	Aqueous Formic Acid, 40 °C, 3 h	TiCl₄/Anisole/DCM, −10 °C	TLC (Silica gel 60 F₂₅₄, EtOAc:MeOH:H₂O 5:1:1)
Critical Drying Parameter	Fluid bed, inlet air dewpoint −40 °C	Vacuum tray, 35 °C, 4 mbar	Karl Fischer, endpoint ≤ 8.5% w/w (trihydrate mon.)
Primary Pharmacopoeial Monograph	USP Cefdinir Monograph	USP Cefixime Monograph	USP-NF 2026 Issue 1

The C-3 vinylthiazole motif in veterinary cephalosporin API production imposes a distinct impurity control challenge absent in human antibiotic synthesis: the tolerability of desacetyl and thiazole ring-opened impurities in ruminant pharmacokinetics. Cefpodoxime Proxetil, a prodrug requiring esterification at the C-4 carboxylic acid, is synthesized from the free acid obtained by first oxidizing the C-3 vinyl group to a phosphonoacetoxy moiety using a peracid-mediated Baeyer-Villiger-type rearrangement (performic acid, generated in situ from H₂O₂ and formic acid at a molar ratio of 1:3.5). The addition of the cephem free acid into the pre-cooled performic acid solution at 0 °C is conducted over 90 minutes to control the exotherm of oxidation. The resulting phosphono intermediate is not isolated but directly esterified with 1-iodoethyl isopropyl carbonate (1.25 eq) in anhydrous N,N-dimethylformamide with anhydrous potassium carbonate (2.0 eq) at 22 °C for 16 hours. This heterogeneous mixture exhibits a mass transfer limitation: the dissolution rate of K₂CO₃ (D50 45 µm) is the rate-determining step, and substitution with amorphous potassium tert-butoxide (1.05 eq at −10 °C) accelerates conversion but increases the formation of the Δ² isomer from 0.5% to 3.8 area% as determined by HPLC (C8 column, 270 nm). The isolated cefpodoxime proxetil ester is an amorphous solid with a glass transition temperature (T_g) of 52 °C (DSC, modulation ± 1 °C every 60 s), rendering conventional spray drying impractical without incorporation of 15% w/w hydroxypropyl methylcellulose acetate succinate (HPMCAS-MF) to elevate T_g to 84 °C. The terminal dosage form is a film-coated tablet containing 200 mg of cefpodoxime as proxetil, with a disintegration time not exceeding 10 minutes (JP 18th Edition, < 6.09 Test for Disintegration). For veterinary suspension formulations, the 1-iodoethyl ester is not pursued; instead, the free acid is milled via jet milling (Venturi pressure 6 bar, grinding pressure 4 bar) to a D90 < 12 µm and formulated as a dry syrup with xanthan gum and sodium benzoate for reconstitution to 100 mg/mL in an oral suspension for dogs.

When the β-Lactam Core Serves as a Hapten: Conjugate Vaccine Carrier Protein Modification

The haptenation of CRM₁₉₇, a non-toxic diphtheria toxin mutant, by the 3-(4-methylthiazole-5-yl)ethenyl cephem skeleton represents a divergent application into immunochemistry for drug allergy diagnosis. The C-4 carboxylic acid is converted to an N-hydroxysuccinimide (NHS) active ester using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC, 1.5 eq) and NHS (2.0 eq) in anhydrous DMF containing 10% v/v 0.1M MES buffer (pH 5.5). The mole ratio of drug hapten to CRM₁₉₇ protein is set at 25:1 to achieve a conjugation ratio of 8–12 mol cephem per mol carrier as determined by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS, sinapinic acid matrix, linear mode). The conjugation is quenched with Tris-HCl buffer (pH 8.0) after 2 hours at 4 °C, and the conjugate is purified via size-exclusion chromatography (Superdex 200 Increase 10/300 GL column, PBS at 0.5 mL/min, UV 280 nm) to remove free hapten and crosslinked high-molecular-weight aggregates eluting at void volume (8.1 mL). The fraction pooled product (eluting at 12.5–14.0 mL) is sterile-filtered and adjuvanted with aluminum phosphate (0.5 mg Al³⁺/mL). The technical limitation is the susceptibility of the vinylthiazole to nucleophilic attack by lysine ε-amino groups at the C-3 methine carbon under the conjugation pH, generating a covalent protein adduct at the side chain rather than through the intended C-4 carboxyl linkage, reducing immunogenic specificity. Pre-blocking with iodoacetamide is not possible as it would alkylate the cephem C-7 amine; thus pH must be strictly maintained at ≤ 5.8 and the molar excess of NHS ester minimized.Producers of liquid masterbatches incorporating antimicrobial cephem additives for medical device polymers utilize a radically different compounding philosophy. The cephem powder, pre-dried in a conical screw vacuum dryer at 45 °C and 1 mbar for 12 hours, is blendered into a thermoplastic polyurethane (TPU) grade with a Shore A hardness of 87 using a co-rotating twin-screw extruder with an L/D ratio of 44:1. The screw profile incorporates three kneading zones at barrel sections 4, 7, and 9, with the cephem fed via a side-feeder at barrel section 6 to minimize thermal history. The melt temperature at the die is maintained at 168 °C ± 3 °C. The challenge is not dispersion but the rapid thermal decomposition of the cephem at screw speeds exceeding 250 rpm due to viscous heat dissipation, yielding a yellow chromophore from thiazole ring degradation detectable as a color shift to b* > 8.0 (CIE L*a*b* spectrophotometer, D65 illuminant). Production-scale validation involves a purge of the hot runner mold using polypropylene at an injection pressure of 1200 bar, with the cephem-TPU masterbatch let down at a 4% weight ratio into medical-grade PEBAX for endotracheal tube cuff extrusion. Bioburden control during extrusion adheres to an initial bioburden of the raw cephem of not more than 100 CFU/g (ISO 11737-1), and the compounded pellet is subsequently sterilized via ethylene oxide per ISO 11135, with a maximum residual EtO limit within the polymer of 4 mg per device after a 14-day forced aeration cycle at 37 °C in a stainless steel aeration cell under positive nitrogen pressure (3 mbar).

Formulation Grade	Addition Ratio (wt%)	Extrusion Melt Pressure (bar)	Residual Solvent (Headspace GC)
TPU Antimicrobial Masterbatch	22% cephem, 78% TPU	83–91	DMF: < 120 ppm
PEBAX Let-Down Ratio (Final Part)	4.0% masterbatch in neat PEBAX	105–115	EtO (post-sterilization): < 1.0 µg/g
γ-Sterilizable PE Compound	8.5% (with 0.3% Vitamin E TPGS)	120–135	Total volatiles: < 0.5%

The generation of enzymatic degradation products by exposure of the 3-ethenylthiazole cephem to cephalosporinase during high-cell-density fermentation of precursor amino acids introduces a biotransformation pathway for downstream metabolite extraction. When E. coli BL21(DE3) expressing a Class C β-lactamase (AmpC) is cultured in fed-batch mode (dissolved oxygen maintained at 30% air saturation, glucose feed rate adjusted to maintain a specific growth rate of 0.15 h⁻¹), the cephem skeleton is converted to the ring-opened metabolite 7-Amino-3-[(Z)-2-(4-methylthiazole-5-yl)ethenyl]-2-cephem-4-carboxylic acid (Δ² isomer) plus thiazole fragments. The clarified fermentation broth is acidified to pH 2.0 with concentrated phosphoric acid, filtered through a 0.45 µm polyvinylidene fluoride (PVDF) capsule, and the metabolite is captured on a strong cation exchange resin (Mitsubishi Chemical DIAION™ SK1B, H⁺ form) with a dynamic binding capacity of 28 mg/mL resin at a linear flow rate of 150 cm/h. Elution employs ammonium hydroxide solution (0.5M) with a step gradient, and the fraction containing the Δ² acid (eluting at 1.8–2.4 column volumes) is lyophilized. The purity by peak area is 94% at 230 nm. This intermediate is further derivatized to produce 3-vinylthiazole propionic acid derivatives utilized as hapten linkers in lateral flow immunoassay development, requiring a free amine content of < 0.02 mmol/g determined by trinitrobenzenesulfonic acid (TNBS) colorimetric assay.For a synthesis pathway producing ceftibuten, a third-generation cephalosporin with a non-esterified carboxyl moiety at the C-2 position of the side chain, the C-7 amine acylation shifts to a mixed anhydride methodology: the 2-(2-aminothiazol-4-yl)-4-carboxycrotonic acid is activated with pivaloyl chloride (1.02 eq) and N-methylmorpholine (1.15 eq) in methylene chloride at −20 °C before addition to the cephem. A distinct side reaction specific to this crotonate side chain is the formation of a Michael adduct by attack of liberated pivalic acid at the γ,δ-double bond, which reduces yield by 4.2% absolute when the pot addition sequence is reversed. The isolated ceftibuten dihydrate is characterized by a pseudo-polymorphic transition at 58% relative humidity (dynamic vapor sorption, 25 °C), converting to the tetrahydrate and exhibiting a 9.8% mass increase. The pharmaceutical formulation is a 400 mg capsule containing ceftibuten dihydrate blended with a desiccant sachet (silica gel, 2 g) integrated into the high-density polyethylene bottle closure to ensure a headspace equilibrium relative humidity below 30% per ICH Q1A(R2) stability protocol. Dissolution is verified in 900 mL of pH 6.8 phosphate buffer at 37 °C ± 0.5 °C, with a paddle speed of 50 rpm (USP Apparatus II), demonstrating a Q of ≥80% after 20 minutes.Nitrosamine risk assessment for the material under the updated EMA/CMDh guidance (EMA/369136/2020) directs focus to the dimethylamine content in the DMAc solvent and the potential for N-nitrosodimethylamine (NDMA) formation during the synthesis and drying unit operations. Headspace GC-MS/MS (triple quadrupole) analysis with a DB-624UI column (30 m × 0.25 mm, 1.4 µm, constant flow 1.2 mL/min helium) of the cephem intermediate dried at 50 °C with an inlet dewpoint of −20 °C reveals NDMA at a level of 1.8 ng/g when DMA contact occurs at pH > 9.0 in the presence of nitrite from a contaminated sodium bicarbonate source. A processing control is introduced: the aqueous bicarbonate solution used for pH adjustment is pre-stripped with nitrogen for a minimum of 4 hours and tested for nitrite using a Griess reagent ion chromatography method with a limit of quantification (LOQ) of 0.01 ppm for nitrite. This reduces NDMA in the final API to below 0.03 ppm, the acceptable intake limit for a drug dosed at 400 mg/day (less than 96 ng/day exposure).

Free Quote

Competitive 7-Amino-3-[(Z)-2-(4-Methylthiazole-5-Yl)Ethenyl]-3-Cephem-4-Carboxylic Acid prices that fit your budget—flexible terms and customized quotes for every order.

For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.

We will respond to you as soon as possible.

Tel: +8615651039172

Email: sales9@bouling-chem.com

Get Free Quote of Bouling Chemical Co., Limited

Flexible payment, competitive price, premium service - Inquire now!

Get A Free Quote Now

Certification & Compliance

7-Amino-3-[(Z)-2-(4-Methylthiazole-5-Yl)Ethenyl]-3-Cephem-4-Carboxylic Acid is manufactured under an ISO 9001 quality system and complies with relevant regulatory requirements.
COA, SDS/MSDS, and related certificates are available upon request. For certificate requests or inquiries, contact: sales9@bouling-chem.com.

More Introduction

`As a key intermediate in the convergent synthesis of third-generation oral cephalosporins, 7-amino-3-[(Z)-2-(4-methylthiazol-5-yl)ethenyl]-3-cephem-4-carboxylic acid (CAS 158601-44-0) functions as the β‑lactam nucleus onto which the characteristic aminothiazolyl‑oxime side chain is grafted. The compound is supplied as a pale‑yellow to off‑white crystalline powder with a molecular formula of C₁₃H₁₃N₃O₃S₂ and a molecular weight of 323.39 g·mol⁻¹. Its singular feature is the (Z)‑configured 2‑(4‑methylthiazol‑5‑yl)ethenyl substituent at C‑3, which remains intact through the final deprotection steps and directly shapes the microbiological spectrum and pharmacokinetic profile of the finished dosage form. The chiral integrity at C‑6 and C‑7—(6R,7R) absolute configuration—is maintained throughout downstream transformations; epimerisation at C‑7 exceeding 0.5 % during activation leads to a corresponding loss of antibacterial potency and constitutes a critical process control point.

Which analytical markers govern batch acceptance?

Release of the intermediate against pharmacopoeial‑aligned specifications relies on a battery of tests that reflect both intrinsic purity and process‑derived impurity burden. Typical acceptance criteria, harmonised across European Pharmacopoeia (Ph. Eur.) and Japanese Pharmacopoeia (JP) general monographs for related substances, include:

Table 1 — Typical release specification for 7‑amino‑3‑[(Z)‑2‑(4‑methylthiazol‑5‑yl)ethenyl]‑3‑cephem‑4‑carboxylic acid
Attribute	Method	Limit
Assay (anhydrous basis)	HPLC, Ph. Eur. 2.2.29	98.0–102.0 %
Individual related substance	HPLC	≤ 1.0 %
Total impurities	HPLC	≤ 2.0 %
(E)‑isomer	HPLC, chiral stationary phase	≤ 0.8 %
Water content	Karl Fischer (Ph. Eur. 2.5.12)	≤ 1.5 %
Sulphated ash	Ph. Eur. 2.4.14	≤ 0.2 %
Heavy metals	Ph. Eur. 2.4.8, Method D	≤ 20 ppm
Specific optical rotation [α]_D²⁰	Ph. Eur. 2.2.7, c=1.0 in 0.1 M HCl	−120° to −128°
Residual solvents: acetone	GC‑HS, Ph. Eur. 2.4.24	≤ 5000 ppm
Residual solvents: dichloromethane	GC‑HS	≤ 600 ppm

The (E)‑isomer is the most consequential single impurity; its presence above the 0.8 % threshold has been shown in pilot‑scale acylation studies to generate the corresponding (E)‑cefditoren stereoisomer, which co‑elutes with the active (Z)‑drug substance under several compendial HPLC conditions and requires preparative separation. Manufacturers therefore deploy preparative crystallisation from isopropanol/water mixtures to maintain the (Z)‑content above 99.2 %. Bulk active acylation of the 7‑amino nucleus proceeds via an activated 2‑(2‑aminothiazol‑4‑yl)‑2‑(methoxyimino)acetyl intermediate. In a standard multipurpose glass‑lined reactor (typical capacity 500–2000 L), the free amine is suspended in dry dichloromethane and silylated with N,O‑bis(trimethylsilyl)acetamide at −5 to 0 °C under nitrogen to generate a soluble silyl ester. The process window is tight: reaction mass temperatures above +2 °C during silylation measurably increase the formation of the Δ²‑to‑Δ³ double‑bond migration product, a degradation marker monitored by in‑process HPLC at 254 nm. Following silylation, the activated side‑chain ester—commonly the benzothiazolyl thioester—is added at −10 °C, and the mixture is allowed to warm to 20–25 °C over 3–4 h. Quenching with aqueous acid, phase separation, and pH‑controlled crystallisation at 3.5–4.0 yields the protected cefditoren acid in molar yields of 85–92 % at scales up to 50 kg input, with batch‑to‑batch impurity profiles varying by less than 0.3 % total related substances when the intermediate assay exceeds 99.0 %.

When light exposure exceeds ICH Q1B confirmatory limits

The vinyl‑thiazole chromophore absorbs strongly in the visible and UVA regions, making the intermediate conspicuously vulnerable to photodegradation. Under ICH Q1B Option 2 confirmatory testing (cool white fluorescent and near‑UV lamp, total illuminance 1.2 × 10⁶ lux·h, integrated near‑UV energy 200 W·h·m⁻²), unprotected powder stored in open Petri dishes develops a visible colour shift from off‑white to deep amber within 8 h. Associated HPLC analysis reveals a 4–6 % increase in total degradation products, primarily the ring‑opened thioester and the C‑3 vinyl‑oxidation sulfoxide. Protectant packaging is therefore mandatory: double polyethylene bags inside an aluminium‑laminated foil pouch, heat‑sealed under nitrogen with an oxygen content verified at ≤ 0.5 % via headspace analyser (Servomex or equivalent). Under these conditions and with storage at −20 ± 5 °C, real‑time stability data from three consecutively manufactured batches demonstrate retest acceptance out to 36 months. Solid‑state thermal degradation follows Arrhenius behaviour with an activation energy of approximately 85 kJ·mol⁻¹ estimated from multi‑temperature accelerated studies at 40, 50, and 60 °C. At 25 °C, the extrapolated decolouration rate corresponds to an observable yellowing time of roughly 12 months, consistent with the practice of shipping the material with gel‑pack temperature control during intercontinental transport. In solution, the compound is markedly less stable: dissolution in ethyl acetate or acetonitrile at 25 °C leads to 2–3 % degradation within 4 h, necessitating freshly prepared solutions for acylation reactions and ruling out the use of recovered mother liquors without intermediate re‑purification. Drying constitutes a further processing bottleneck identified on production‑scale agitated nutsche filter‑dryers. The wet cake retains 12–15 % solvent after filtration; vacuum drying at 35–40 °C and 10–20 mbar for 8–10 h reliably reduces water content below 1.5 % and residual acetone below 5000 ppm. However, agitator speed settings above 25 rpm in the final dry phase generate mechanical attrition and produce fines that increase the specific surface area, which in turn accelerates surface oxidation upon exposure to ambient air. This effect is quantified by a decrease in tapped bulk density from a target 0.45–0.55 g·cm⁻³ to 0.30–0.35 g·cm⁻³ and a corresponding 0.8–1.2 % rise in total impurities after 24 h of open‑container holding in a 25 °C, 60 % RH environment.

Comparative substitution patterns at position 3

The biological and process‑chemistry profile of the intermediate becomes most distinct when placed alongside the other 7‑amino cephem nuclei that populate cephalosporin supply chains. The table below captures the divergence in intrinsic reactivity and associated manufacturing discipline.

Table 2 — Comparison of selected 7‑amino‑3‑cephem‑4‑carboxylic acid derivatives
Derivative	C‑3 substituent	Molecular weight (g·mol⁻¹)	Typical assay requirement	Key process sensitivity	Corresponding API example
7‑ACA	‑CH₂OCOCH₃	272.28	≥ 98.5 %	Hydrolysis of acetoxy group under basic conditions	Cefotaxime
7‑ADCA	‑CH₃	214.24	≥ 99.0 %	Limited β‑lactam ring stability in strong acid	cephalexin
7‑AVCA (present compound)	‑(Z)‑CH=CH‑(4‑methylthiazol‑5‑yl)	323.39	≥ 98.0 %	Photo‑ and thermal isomerisation of the vinyl group	Cefditoren
6‑APA	N/A (penam core)	216.24	≥ 99.0 %	Opening of the thiazolidine ring by electrophiles	Amoxicillin

The C‑3 vinyl‑thiazole substituent, absent in 7‑ACA and 7‑ADCA, extends the conjugated system and reduces the basicity of the adjacent cephem double bond. This translates into a slower rate of β‑lactam ring opening in weakly acidic media compared with 7‑ADCA, a property exploited in the final purification of cefditoren pivoxil where the prodrug ester is cleaved under conditions that would degrade the corresponding 3‑methyl analogue. Simultaneously, the bulkier ethenyl‑heterocycle retards the diffusion‑limited acylation rate: comparative kinetic measurements in dichloromethane at 0 °C using the same activated thioester show that the 7‑amino group of 7‑AVCA is acylated roughly 2.3 times slower than that of 7‑ACA, a difference that reactor scale‑up models must accommodate through extended dosing or higher excess of the activated side chain (1.5–1.8 eq. versus 1.2 eq. for 7‑ACA). Handling requirements diverge further from the parent 7‑ACA and 7‑ADCA intermediates. While 7‑ACA can be stored at 2–8 °C in HDPE drums with silica‑gel desiccants for 24 months, the vinyl‑thiazole intermediate mandates −20 °C storage in nitrogen‑flushed, moisture‑impermeable pouches, and any excursion above 0 °C for more than 72 h during shipment must be logged as a temperature deviation subject to re‑testing. These constraints arise directly from the compound’s low glass transition temperature of approximately 12 °C as measured by differential scanning calorimetry, which renders the amorphous fraction prone to collapse and water uptake at ambient conditions, triggering hydrolysis. Dissolved‑oxygen sensitivity in the formulated drug substance has its origin in the same vinyl‑thiazole entity. In the final steps, manufacturers of cefditoren pivoxil must limit the oxygen content in the recrystallisation solvent to < 1 ppm by sparging with argon, as the sulfoxide impurity formed via singlet‑oxygen addition grows to 0.15 % for every 1 ppm increase in dissolved O₂. This sensitivity is not exhibited by 7‑ACA‑ or 7‑ADCA‑derived cephalosporins, where the C‑3 substituent lacks the extended conjugation that promotes energy transfer from excited‑state oxygen.

Residual solvent entanglement in crystal lattice

Powder X‑ray diffraction (XRPD) patterns of the micronised intermediate frequently display anomalous low‑angle reflections that co‑vary with the acetone content measured by headspace GC. When acetone is reduced below 2000 ppm by prolonged vacuum drying at 40 °C, these reflections lose intensity and the bulk powder becomes X‑ray amorphous, coinciding with a sharp increase in residual water sorption from 1.2 % to 2.5 % in 24 h at 50 % RH. This behaviour indicates that acetone occupies clathrate‑like positions within the crystal lattice, stabilising a hydrate‑resistant polymorph. Consequently, the drying protocol deliberately targets a residual acetone level of 3000–4500 ppm rather than pursuing exhaustive solvent removal, a nuance that distinguishes the post‑synthesis work‑up of this intermediate from that of 7‑ACA, where acetone typically falls below 1000 ppm without polymorphic penalty. Published data for this specific configuration is limited, but comparable lattice‑solvent stabilisation has been documented for certain cefuroxime intermediates and informs the risk assessment when drying parameters are transferred between contract manufacturing sites. The particle‑size distribution (PSD) of the micronised material, determined by laser diffraction (Malvern Mastersizer 3000, dry dispersion), is specified as D₁₀ 1–3 µm, D₅₀ 8–15 µm, D₉₀ ≤ 40 µm. Tighter PSD control becomes necessary when the intermediate is used in direct‑conduction tray drying of the pivoxil prodrug, where overlarge crystals impede solvent diffusion and under‑drying of the centre cut has resulted in batch rejection in at least one FDA‑cited 483 observation. Jet‑milling under nitrogen at a classifier speed of 8000 rpm and a grinding pressure of 7 bar reliably achieves the target D₅₀ without generating the amorphous surface layers that appear above 12 000 rpm, as verified by dynamic vapour sorption (DVS) isotherm hysteresis opening above 0.5 %. Finally, the incompatibility profile of the 7‑amino intermediate with amine‑bearing reagents warrants explicit notation. The nucleophilic 7‑amino group, when exposed to even catalytic quantities of tertiary amines such as triethylamine or N‑methylmorpholine in aprotic solvents, undergoes aza‑Michael addition to the C‑3 vinyl group. The resulting bridged dimer has been detected in LC‑MS analyses at levels up to 2.5 % after 6 h of contact at 25 °C. This precludes the use of amine‑scavenging solid‑phase resins during the acylation work‑up and requires instead that any acid‑scavenging base be limited to inorganic bicarbonates or weak organic bases (pK_a ≤ 4.5) with minimal vinyl‑addition reactivity, a constraint not shared by 7‑ACA or 7‑ADCA processing streams.